tldrdailynews.com logo

Novartis to Acquire Avidity Biosciences for $12 Billion in Cash

1 min read
Source: CNBC
Novartis to Acquire Avidity Biosciences for $12 Billion in Cash
Photo: CNBC
TL;DR

Novartis is acquiring U.S. biotech firm Avidity Biosciences for about $12 billion in cash, aiming to expand its RNA therapeutics portfolio and boost growth, with the deal expected to close in the first half of 2026 after Avidity spins out some of its business units.

Topics:top-newsbusiness#acquisition#avidity-biosciences#biotech#business#novartis#rna-therapeutics
Share this article
  1. Novartis to buy U.S. biotech firm Avidity Biosciences for about $12 billion in cash  CNBC
  2. Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline  Novartis
  3. Novartis Said to Near at Least $70-Per-Share Deal for Avidity  Bloomberg.com
  4. Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports  Reuters
  5. Novartis to buy RNA drugmaker Avidity Biosciences for $12B  Endpoints News

Want the full story? Read the original reporting

Read on CNBC